n.c.a. Lutetium-1772021-09-16T22:16:03+00:00


Our isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers, such as prostate cancer. Our current focus includes production of non-carrier-added lutetium-177. The unique advantages of our n.c.a. Lu-177 production process include an exclusive processing technology, flexibility for irradiation, stable isotope enrichment capability, fewer logistical challenges in transport, and a cleaner and safer production method.

SHINE Lu-177 Product Box 3

Therapeutics in the news

Contact our Lu-177 sales team


Go to Top